theHeart.org - Hypertension

Sen Grassley questions top medical schools about ghostwriting

Fri, 20 Nov 2009 13:15:28 EST

As part of his mission to see more financial transparency in medicine, Sen Grassley has asked eight top US medical schools about their policies on ghostwriting.

ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment

Thu, 19 Nov 2009 14:00:01 EST

New 10-year mortality and morbidity data confirm the original trial conclusions, they say, that while amlodipine and lisinopril are not superior to chlorthalidone on any outcome, chlorthalidone is superior to these agents on one or more secondary end points. Full agreement with this conclusion in the community, though, is still hard to come by.

EFFECT: Public reporting of hospital performance improves quality of care?

Thu, 19 Nov 2009 10:00:55 EST

Publicly released report cards based on hospital performance did not result in a measurably greater systemwide improvement in two composite AMI or CHF process-of-care indicators in a Canadian study. But they did appear to stimulate some important changes in delivery of care that could have led to some better outcomes.

HEAAL: High-dose trumps low-dose ARB for heart failure in the ACE-inhibitor intolerant

Tue, 17 Nov 2009 08:15:58 EST

UPDATED WITH COMMENTARY // The randomized trial, which compared losartan dosages of 150 mg/day and 50 mg/day, "makes a strong case for the value of incremental inhibition of the renin-angiotensin system," its authors say.

Canadian confusion: Primary-care docs lack knowledge of CVD risk factors, prevention

Sun, 15 Nov 2009 09:00:30 EST

Family doctors and general practitioners in Canada are confused about cardiovascular risk assessment in primary prevention, a new survey reveals.

What's going to be hot at AHA 2009?

Wed, 11 Nov 2009 09:00:54 EST

Anticipation is building for full trial results from ARBITER 6-HALTS, plus a better understanding of what went wrong with cangrelor in the CHAMPION trials. Also in the lineup are updates from PLATO, RE-LY, ALLHAT, BARI 2D, STICH, CASCADE, POPULAR, HEARTMATE II, and many more. Indeed, this year's "late-breaking" sessions include more than 30 trials over five days.

Echocardiographic evidence of PAH often doesn't trigger referral to a specialist

Tue, 10 Nov 2009 11:00:48 EST

Only one in four patients with echocardiographic evidence of pulmonary arterial hypertension is being referred for further evaluation.

Ambrisentan effective long-term for pulmonary arterial hypertension

Mon, 09 Nov 2009 17:00:00 EST

New data from the extension phase of two pivotal trials of the endothelin-receptor antagonist ambrisentan support its use as part of a long-term strategy for the treatment of pulmonary arterial hypertension.

Obesity may top hypertension as risk factor for LA enlargement

Mon, 09 Nov 2009 17:00:00 EST

Obesity and hypertension were major independent risk factors for left atrial enlargement (itself a risk factor for atrial fibrillation) in an observational, population-based study, but obesity was the strongest predictor.

Not all metabolic syndrome is created equal: Framingham Offspring analysis

Thu, 05 Nov 2009 11:45:03 EST

The syndrome (defined by ATP III criteria) can predict increased cardiovascular and mortality risk or not, depending on which three of five risk factors contributed to the diagnosis, a cohort study suggests; its investigators caution that their observations are only preliminary.

Adding fuel to the J-curve fire; debate is reignited

Wed, 04 Nov 2009 14:30:56 EST

More discussion about the J-curve in hypertension is published this week; one expert believes the undue attention being paid to this subject might discourage doctors from treating high blood pressure aggressively.

Another in-hospital CV risk marker: 24-hour shifts with overnight on-call duty

Wed, 04 Nov 2009 09:45:43 EST

Long work shifts with nighttime on-call duty, with the inevitable interruptions of sleep, are associated with ECG, blood-pressure, and biochemical changes associated with increased cardiovascular risk, suggests a randomized crossover study that hints at a sustained effect on the risk markers if the 24-hour shifts happen too frequently.

US updates advice on perioperative beta-blocker use in noncardiac surgery

Tue, 03 Nov 2009 14:30:32 EST

A US update on the perioperative use of beta blockers for noncardiac surgery is, says the lead author, "similar" to recent European guidance on this issue.

Combined home/GP hypertension control program successful in Pakistan

Mon, 02 Nov 2009 17:00:00 EST

A synergistic approach of educating general practitioners about hypertension control together with a program to send lay workers into people's homes to educate them about the management of high blood pressure has proven successful in low- to middle-income households in Pakistan.

ACE inhibitors of benefit in ischemic heart disease patients with preserved LV function

Mon, 19 Oct 2009 17:00:00 EDT

Patients with ischemic heart disease and preserved LV function on standard therapy will gain additional benefit from taking ACE inhibitors, a new review concludes. The same cannot be said for ARBs, a drug class for which the evidence is much weaker, but these are a good substitute in those who cannot tolerate ACE inhibitors, the authors say.

Expanded indication for telmisartan

Mon, 19 Oct 2009 13:30:16 EDT

The drug can now be used to reduce the risk of MI, stroke, or death from cardiovascular causes in patients 55 years of age or older who are intolerant to ACE inhibitors but at high risk for cardiovascular events.

Racial background woefully underreported in CV trials

Thu, 15 Oct 2009 13:15:10 EDT

Two-thirds of the 156 trials considered by the AHA in preparing a recent guideline failed to even record the ethnic backgrounds of participants, a new study has found. The researchers call for the reporting of race/ethnicity to be mandatory in all clinical trials, and they suggest medical journals should enforce this policy.

Diuretics effective as second-line therapy for hypertension

Tue, 13 Oct 2009 12:00:48 EDT

Diuretics, especially hydrochlorothiazide, are as effective when given as second-line therapy for high blood pressure as they are when used as initial treatment, according to the first review to look at this issue.

High adherence to antihypertensive therapy lowers cardiovascular risk

Fri, 09 Oct 2009 13:30:36 EDT

Newly diagnosed hypertensive individuals who stuck to their antihypertensive therapy had a significantly lower risk of cardiovascular events than low adherers.

Mercury/blood-pressure link should guide fish choices

Tue, 06 Oct 2009 16:45:03 EDT

An association seen between mercury levels and blood pressure, even after considering omega-3s and selenium, has researchers warning about the need to weigh the risks and benefits of fish consumption and to steer clear of bigger predators.

China death toll due to hypertension worse than predicted

Tue, 06 Oct 2009 14:15:24 EDT

The first prospective study using real data to inform the number of people suffering from and dying due to high blood pressure in China finds the problem is much worse than previously thought. A number of initiatives are planned to try to tackle this crisis.

Simple, fixed-dose drug bundle may lower MI and stroke risk

Tue, 06 Oct 2009 10:15:41 EDT

A bundle of medium doses of a statin and an ACE inhibitor appears to lower CV risk in high-risk individuals, an observational study suggests, but critics caution that these are early days.

New "principles" on authorship and COI from PhRMA get mixed response

Fri, 02 Oct 2009 12:00:10 EDT

The "Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results" echo recent standards set by medical journal editors, but some observers say the document, which has no penalty component, lacks real teeth.

Time to act: Cardiologists, diabetes docs, and psychiatrists urged to work together to tackle CVD in the mentally ill

Wed, 30 Sep 2009 14:00:04 EDT

Doctors from across the specialties of cardiology, diabetes, and psychiatry are being urged to collaborate to improve care for the mentally ill, who are more likely to die from cardiovascular disease than any other cause.

BCIS-1 trial: "Bailout" intra-aortic balloon pump beats elective use in low EF/high-risk patients

Tue, 29 Sep 2009 10:45:47 EDT

The study provides an important answer to a question that has divided some interventionalists. Those who "swear" by IABP use for all high-risk, low-EF patients should rethink their practice. In hypotensive patients and those with cardiogenic shock, IABPs play a key role.

BNP-boosting gene variant hints at possible screening, cardioprotective roles

Fri, 25 Sep 2009 10:45:02 EDT

A single-nucleotide polymorphism associated with chronically raised natriuretic-peptide levels is common enough to potentially influence interpretation of BNP and NT-proBNP assays under some circumstances, researchers say; there is increasing evidence that the gene variant may enhance survival in some patient groups.